GlassScriptPhysician profile
Hasan Abualula
NPI 1508008228
$16,071.39
in general payments reported to CMS, 2019-2025
31 companies · $2,135 in 2025
The $2,135 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,339 · 2020: $1,558 · 2021: $2,434 · 2022: $3,124 · 2023: $2,841 · 2024: $2,640 · 2025: $2,135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,588 · Education: $28.41.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,588.12 |
| Education | $28.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,316.38 | 2019-2025 | Enbrel, Evenity, Tavneos |
| Abbvie INC. | $3,184.37 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Janssen Biotech, INC. | $1,821.71 | 2020-2025 | Tremfya, Simponi Aria |
| Ucb, INC. | $1,575.38 | 2019-2025 | Cimzia, Bimzelx |
| Pfizer INC. | $1,207.19 | 2019-2025 | |
| Horizon Therapeutics Plc | $936.96 | 2019-2023 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $925.11 | 2019-2025 | |
| Lilly USA, LLC | $882.48 | 2019-2025 | Taltz, Zepbound, Olumiant |
| Glaxosmithkline, LLC. | $427.24 | 2019-2025 | Benlysta, Nucala |
| E.R. Squibb & Sons, L.L.C. | $283.66 | 2020-2025 | Orencia |
| Astrazeneca Pharmaceuticals LP | $241.02 | 2021-2025 | Saphnelo |
| Genzyme Corporation | $216.20 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.95 | 2022-2024 | Cyltezo, Ofev |
| Genentech USA, INC. | $121.34 | 2019-2023 | Ocrevus |
| Ani Pharmaceuticals, INC. | $105.38 | 2024-2025 | Sovuna, Purified Cortrophin Gel |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $86.96 | 2019 | |
| Boston Scientific Corporation | $80.01 | 2020-2025 | Watchman Flx |
| Aurinia Pharma U.S., INC. | $77.21 | 2022-2025 | Lupkynis |
| Organon LLC | $67.93 | 2023-2024 | Renflexis, Hadlima |
| Fresenius Kabi USA, LLC | $66.57 | 2023 | Idacio |
| Mallinckrodt Enterprises LLC | $64.56 | 2019 | |
| Tanabe Pharma America, INC. | $37.50 | 2021 | |
| Paratek Pharmaceuticals, INC. | $37.15 | 2022 | |
| Sobi, INC | $33.28 | 2022-2023 | |
| Radius Health, INC. | $27.68 | 2023 | |
| Merck Sharp & Dohme LLC | $21.48 | 2024 | Recarbrio, Zerbaxa, Dificid |
| Ethicon US, LLC | $19.43 | 2024 | Stratafix, Dermabond |
| Avion Pharmaceuticals | $15.43 | 2020 | |
| Bioventus LLC | $11.47 | 2020 | |
| Amarin Pharma, INC. | $11.44 | 2019 | |
| Novo Nordisk INC | $10.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hasan Abualula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.